Adam Thomas reveals tough two-year health battle that's left him in pain every day
Adam Thomas has opened up about his challenging battle with arthritis, revealing the impact it’s had on his life during a candid chat with Susanna Reid.
Healio17h
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...
Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...
Royalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
Endocrinology Advisor12h
FDA Approves Tocilizumab Biosimilar Avtozma
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
rheumatologyadvisor1h
FDA Extends Review of Elamipretide for Barth Syndrome
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
PipelineReview.com23h
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...